Please wait while we load the requested 8-K report or click the link below:
https://last10k.com/sec-filings/report/1557746/000155837019008933/f8-k.htm
May 2024
March 2024
February 2024
February 2024
January 2024
December 2023
November 2023
November 2023
September 2023
August 2023
Please wait while we load the requested 8-K report or click the link below:
https://last10k.com/sec-filings/report/1557746/000155837019008933/f8-k.htm
Compare this 8-K Corporate News to its predecessor by reading our highlights to see what text and tables were removed , added and changed by Aclaris Therapeutics, Inc..
Aclaris Therapeutics, Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2019 10-K Annual Report includes:
Material Contracts, Statements, Certifications & more
Aclaris Therapeutics, Inc. provided additional information to their SEC Filing as exhibits
Ticker: ACRSEvents:
CIK: 1557746
Form Type: 8-K Corporate News
Accession Number: 0001558370-19-008933
Submitted to the SEC: Wed Oct 16 2019 9:54:06 PM EST
Accepted by the SEC: Thu Oct 17 2019
Period: Tuesday, October 15, 2019
Industry: Pharmaceutical Preparations